Home
About
Overview
Sharing Data
ORCID
Help
History (19)
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Development and clinical indications of cetuximab.
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands.
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. JCO Precis Oncol. 2023 Sep; 7:e2200445.
View in:
PubMed
subject areas
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Humans
Lung Neoplasms
Molecular Targeted Therapy
Neoadjuvant Therapy
Neoplasm Staging
Protein Kinase Inhibitors
authors with profiles
Ravi Salgia